| Assessment Status | Rapid Review complete |
| HTA ID | 24021 |
| Drug | Ciltacabtagene autoleucel |
| Brand | Carvykti® |
| Indication | For the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide. |
| Assessment Process | |
| Rapid review commissioned | 04/06/2024 |
| Rapid review completed | 08/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ciltacabtagene autoleucel for this indication compared with the current standard of care. |
